Becton Dickinson's Suppliers recorded an increase in sales by 39.86 % year on year in Q3 2026, sequentially sales grew by 32.89 %, Becton Dickinson recorded an increase in cost of sales by 7.11 % year on year, sequentially cost of sales grew by 4.22 % in Q3.
Becton Dickinson's Suppliers recorded an increase in sales by 39.86 % year on year in Q3 2026, sequentially sales grew by 32.89 %, Becton Dickinson recorded increase in cost of sales by 7.11 % year on year, sequentially cost of sales grew by 4.22 % in Q3.
The company operates in a competitive supplier environment where procurement strategies focused on cost-efficiency may affect innovation, quality, patient access, and supplier retention. Legislative changes to Medicare, Medicaid, and the Affordable Care Act have the potential to influence healthcare coverage, demand, and product pricing. Governments in China and other countries implement measures such as competitive bidding, tenders, price regulation through volume-based procurement programs (VoBP), payback provisions, and reimbursement policy adjustments to manage healthcare costs, which can negatively impact revenues. The company's customers include pharmaceutical and biotechnology firms, academic institutions, government laboratories, and private foundations, many of which depend on government grants from entities like the U.S. National Institutes of Health. Government funding for research and development is unpredictable and declined in fiscal year 2025 due to policy changes, economic conditions, and the possibility of government shutdowns. Future growth relies on new product development, which requires substantial investment and faces risks related to regulatory approvals, manufacturing, intellectual property rights, and market acceptance.
Becton Dickinson's Comment on Supply Chain
The company operates in a competitive supplier environment where procurement strategies focused on cost-efficiency may affect innovation, quality, patient access, and supplier retention. Legislative changes to Medicare, Medicaid, and the Affordable Care Act have the potential to influence healthcare coverage, demand, and product pricing. Governments in China and other countries implement measures such as competitive bidding, tenders, price regulation through volume-based procurement programs (VoBP), payback provisions, and reimbursement policy adjustments to manage healthcare costs, which can negatively impact revenues. The company's customers include pharmaceutical and biotechnology firms, academic institutions, government laboratories, and private foundations, many of which depend on government grants from entities like the U.S. National Institutes of Health. Government funding for research and development is unpredictable and declined in fiscal year 2025 due to policy changes, economic conditions, and the possibility of government shutdowns. Future growth relies on new product development, which requires substantial investment and faces risks related to regulatory approvals, manufacturing, intellectual property rights, and market acceptance.
BDX's Suppliers Net Income grew by
BDX's Suppliers Net margin grew in Q3 to
135.08 %
14.23 %
BDX's Suppliers Net Income grew by 135.08 %
BDX's Suppliers Net margin grew in Q3 to 14.23 %
Becton Dickinson's Suppliers Sales Growth
in Q3 2026 by Industry
Sources:
Becton Dickinson And Company's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Becton Dickinson And Company’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
7.38 %